Cannabinoid and Orexigenic Systems Interplay as a New Focus of Research in Alzheimer's Disease

JB Rebassa, T Capó, J Lillo, I Raïch… - International Journal of …, 2024 - mdpi.com
Alzheimer's disease (AD) remains a significant health challenge, with an increasing
prevalence globally. Recent research has aimed to deepen the understanding of the …

Therapeutic molecular insights into the active engagement of cannabinoids in the therapy of Parkinson's disease: a novel and futuristic approach

V Jain, T Behl, A Sehgal, S Singh, N Sharma… - Neurotoxicity …, 2023 - Springer
Parkinson's disease is a neurodegenerative disorder which is characterised mostly by loss
of dopaminergic nerve cells throughout the nigral area mainly as a consequence of …

Bioactive lipids and their metabolism: New therapeutic opportunities for Parkinson's disease

W Shen, L Jiang, J Zhao, H Wang, M Hu… - European Journal of …, 2022 - Wiley Online Library
Parkinson's disease (PD) is a neurological disorder characterized by motor dysfunction,
which can also be associated with non‐motor symptoms. Its pathogenesis is thought to stem …

The interplay between CB2 and NMDA receptors in Parkinsons disease

J Lillo, I Raich, JB Rebassa, T Capo, P Badia… - bioRxiv, 2025 - biorxiv.org
Parkinson's disease (PD) is a progressive neurological disorder that affects movement,
causing symptoms such as tremors, stiffness, slowness, and balance problems due to the …

[PDF][PDF] In silico molecular docking analysis of selected phytoconstituents from Psydrax dicoccos (Gaertn.) against Parkinson’ s disease

PS Mahalakshmi - International Journal of Green Pharmacy …, 2021 - greenpharmacy.info
In silico molecular docking analysis of selected phytoconstituents from Psydrax dicoccos (Gaertn.)
against Parkinson’s disease Page 1 International Journal of Green Pharmacy • Jul-Sep 2021 • …